Kathryn Guarini

CIK: 0001992352

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (37.5%)

Position reduction

Option Exercises (M)3 (37.5%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

REGN

REGENERON PHARMACEUTICALS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

REGN
REGENERON PHARMACEUTICALS, INC.
Oct 30, 2026
Exercise(M)
Direct
400 shares at avg. $719.37$288K
REGN
REGENERON PHARMACEUTICALS, INC.
Oct 30, 2026
Sale(S)
Direct
400 shares at avg. $900.00$360K
REGN
REGENERON PHARMACEUTICALS, INC.
Sep 2, 2026
Exercise(M)
Direct
400 shares at avg. $719.37$288K
REGN
REGENERON PHARMACEUTICALS, INC.
Sep 2, 2026
Sale(S)
Direct
400 shares at avg. $850.00$340K
REGN
REGENERON PHARMACEUTICALS, INC.
Aug 10, 2026
Sale(S)
Direct
400 shares at avg. $800.00$320K
REGN
REGENERON PHARMACEUTICALS, INC.
Aug 10, 2026
Exercise(M)
Direct
400 shares at avg. $719.37$288K
REGN
REGENERON PHARMACEUTICALS, INC.
Jan 2, 2026
Award(A)
Direct
155 shares-
REGN
REGENERON PHARMACEUTICALS, INC.
Jan 2, 2025
Award(A)
Direct
166 shares-

		Type	Shares	Price		Ownership
Oct 30, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Exercise(M)	400	$719.37	$287,748	Direct
Oct 30, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Sale(S)	400	$900.00	$360,000	Direct
Sep 2, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Exercise(M)	400	$719.37	$287,748	Direct
Sep 2, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Sale(S)	400	$850.00	$340,000	Direct
Aug 10, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Sale(S)	400	$800.00	$320,000	Direct
Aug 10, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Exercise(M)	400	$719.37	$287,748	Direct
Jan 2, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Award(A)	155	-	$0	Direct
Jan 2, 2025	REGN REGENERON PHARMACEUTICALS, INC.	Award(A)	166	-	$0	Direct

1-8 of 8 transactions

About Guarini Kathryn

Guarini Kathryn (SEC CIK 0001992352) files insider reports with the SEC as Director of REGENERON PHARMACEUTICALS, INC. (REGN).

Signal8 holds 5 ownership filings by Guarini Kathryn, all Form 4s, filed between Jan 6, 2025 and Nov 3, 2026. Those filings report 8 transactions, from Jan 2, 2025 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Guarini Kathryn's filings is in TARRYTOWN, NY.

Recent filings by Guarini Kathryn

Oct 30, 2026: Option exercise of REGN shares (Form 4, code M).
Oct 30, 2026: Open-market sale of REGN shares (Form 4, code S).
Sep 2, 2026: Option exercise of REGN shares (Form 4, code M).
Sep 2, 2026: Open-market sale of REGN shares (Form 4, code S).
Aug 10, 2026: Open-market sale of REGN shares (Form 4, code S).

Other insiders filing for REGENERON PHARMACEUTICALS, INC. (REGN)

BROWN MICHAEL S, Director
McCourt Marion, EVP Commercial
MURPHY ANDREW J, Co-Chief Scientific Officer
LAROSA JOSEPH J, EVP General Counsel and Secret
Fenimore Christopher R., EVP Finance CFO
Zoghbi Huda Y, Director

How to read Form 4 transaction codes